Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 27, 2019 - Issue 1
Submit an article Journal homepage
428
Views
33
CrossRef citations to date
0
Altmetric
Original Articles

Rapid and Sustained Efficacy of Golimumab in the Treatment of Multirefractory Uveitis Associated with Behçet’s Disease

Claudia FabianiDepartment of Ophthalmology, Humanitas Research Center, Rozzano (Milan), ItalyCorrespondence[email protected] [email protected]
, MD, PhD,
Jurgen SotaResearch Center of Systemic Autoinflammatory Diseases, Behçet’s Disease Clinic and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy
, MD,
Donato RiganteInstitute of Pediatrics, Università Cattolica Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy
, MD, PhD,
Antonio VitaleResearch Center of Systemic Autoinflammatory Diseases, Behçet’s Disease Clinic and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy
, MD,
Giacomo EmmiDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy
, MD, PhD,
Lorenzo VannozziDepartment of Surgery and Translational Medicine, Eye Clinic, University of Florence, Florence, Italy
, MD,
Rossella FranceschiniOphthalmology Unit of the Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy
, MD,
Daniela BacheriniDepartment of Surgery and Translational Medicine, Eye Clinic, University of Florence, Florence, Italy
, MD,
Bruno FredianiResearch Center of Systemic Autoinflammatory Diseases, Behçet’s Disease Clinic and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy
, MD,
Mauro GaleazziResearch Center of Systemic Autoinflammatory Diseases, Behçet’s Disease Clinic and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy
, MD,
Gian Marco TosiOphthalmology Unit of the Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy
, MD, PhD &
Luca CantariniResearch Center of Systemic Autoinflammatory Diseases, Behçet’s Disease Clinic and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, ItalyORCID Iconhttp://orcid.org/0000-0002-7352-1275
, MD, PhD ORCID Icon show all
Pages 58-63 | Received 31 May 2017, Accepted 03 Jul 2017, Published online: 05 Oct 2017
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

ABSTRACT

Purpose: To evaluate golimumab (GOL) efficacy in the management of Behçet’s disease (BD)-related uveitis.

Methods: We retrospectively collected data from 5 patients (8 eyes) with at least two recent relapses of uveitis, treated with GOL at the standard dose of 50 mg every 4 weeks.

Results: A complete control of intraocular inflammation was observed in 7/8 eyes (87.5%) at 12-month follow-up. The number of relapses 12 months before and after GOL initiation was 11 and 1, respectively. At baseline, four eyes had active retinal vasculitis (RV). At 3-month follow-up evaluation RV resolved in all eyes. Mean Best Corrected Visual Acuity was 6.93 ± 4.34 at baseline and 7.32 ± 3.87 at 12-months follow-up.

Conclusion: We confirm GOL efficacy in reducing intraocular inflammation in BD, both in term of reduction in the number of uveitis relapses and in achieving a prompt resolution of active RV.

DECLARATION OF INTEREST

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related Research Data

Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
Source: Elsevier BV
Update on the treatment of Behçet's syndrome
Source: Springer Science and Business Media LLC
EULAR recommendations for the management of Behçet disease
Source: BMJ
Epidemiology and clinical course of Behçet's disease in the Reggio Emilia area of Northern Italy: A seventeen-year population-based study
Source: Wiley
A case of neuromyotonia in Behçet disease during TNF-α antagonist therapy.
Source: Springer Science and Business Media LLC
Controversies in Behçet Disease
Source: Informa UK Limited
Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience.
Source: Hindawi Publishing Corporation
Expert opinion on the use of biological therapy in non-infectious uveitis.
Source: HAL CCSD

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.